Leveragen and Moderna have entered a research, option and licence agreement to advance the development of various therapeutics.
The multi-target deal will utilise Leveragen’s fully human single-domain antibody discovery platform for therapeutic advancement.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Leveragen will use this unique platform to create several binding modules against therapeutic targets chosen by Moderna.
Moderna holds the option to obtain sole rights for the ensuing development and commercialisation of the resulting therapeutic assets.
Leveragen will oversee the discovery of single-domain antibody sequences for various targets under the collaboration.
Upon Moderna’s exercising its commercial option, the company will take over the subsequent development and commercialisation activities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLeveragen is entitled to receive an undisclosed upfront payment and research funding, in addition to milestone payments on meeting development, regulatory and commercial goals from Moderna.
The company could also receive tiered royalty payments on sales of the products worldwide.
Leveragen, a genetic engineering company, uses its technologies to transform the discovery of biologic modalities for the next generation of therapeutic and diagnostic applications.
The company’s Singularity Sapiens Mouse is a product of advanced CRISPR gene editing and chromosome engineering technologies, producing heavy chain antibodies from the complete human VH [variable heavy] repertoire.
Its AI-powered, NGS [next generation sequencing]-driven antibody discovery pipeline has been instrumental in generating fully human single-domain antibodies.
Leveragen founder and CEO Weisheng Chen stated: “Existing models for single domain antibody discovery often encounter challenges including restricted antibody diversity and suboptimal immune responses. These issues are a direct result of the limitations associated with conventional transgenic technologies.
“We’ve solved these problems with a targeted approach, creating the Singularity Sapiens Mouse — an industry-leading model with the complete human VH repertoire and robust immune responses. Our partnership with Moderna further expands the potential of using single domain antibodies in mRNA therapeutics, offering promising opportunities to address unmet medical needs.”
In May 2024, the company signed a multi-target commercial licence deal with 92Bio to develop therapeutic antibodies.
